Oncogenic KRAS regulates glucose and glutamine metabolism in pancreatic cancer cells.MUC1 overexpression leads to increased glucose metabolism.p53 functions predict the sensitivity of pancreatic cancer tumors to glycolytic inhibition.Targeting alpha-ketoglutarate dehydrogenase function by CPI-613 to slow mitochondrial metabolism.The antidiabetic drug, metformin, targets pancreatic cancer stem cells.Combined therapy is used to target pancreatic metabolism heterogeneity.
Camelo, F., & Le, A. (2018). The intricate metabolism of pancreatic cancers. In Advances in Experimental Medicine and Biology (Vol. 1063, pp. 73–81). Springer New York LLC. https://doi.org/10.1007/978-3-319-77736-8_5